fashion -WSS

fashion

author：comprehensive 2025-09-28 02:32:25 - browse：8927

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Health Care Service Corp to buy Cigna Medicare Advantage plans

hotspot

WSS

Judge sides with young activists in first

Wegovy leads to weight loss. Can it treat depression, too?

BMS, looking to build heart drug business, turns to AI for diagnosis

Syphilis numbers in the United States reach record heights

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Novo Nordisk touts Wegovy study, but still struggling with supply

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Jerome Adams on the need for new antivirals for Covid

Biogen’s boardroom scandal saddles CEO with first crisis

Drug repurposing or repositioning? The language matters

Biogen walks away from Aduhelm, years after polarizing approval

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medicare drug price negotiation legal challenge met with skepticism

Supreme Court strikes down use of affirmative action

Illinois Supreme Court finds assault weapons ban constitutional

After affirmative action ruling, medical educators look to 'holistic review'

Surge in Apellis stock fueled by confidence in safety of its eye drug

explore

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Bird flu researchers hone in on Finland’s mink farms

Bernie Sanders is gearing up to subpoena pharma CEOs

FTC sues over Novant Health acquisition of two N.C. hospitals

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Dozens dead from Maui wildfires: What we know about the victims

hotspot

hotspot

explore

leisure time